Suzetrigine as a novel treatment for headache disorders: A case series.
Molly Fensterwald, Jordan Johnson, Angel Moreno...
https://pubmed.ncbi.nlm.nih.gov/42249666/Actively Recruiting
Led by Vertex Pharmaceuticals Incorporated · Updated on 2026-10-15
1100
Participants Needed
76
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness, safety, and tolerability of Suzetrigine SUZ in adults with pain caused by diabetic peripheral neuropathy DPN. This Phase 3 clinical trial compares Suzetrigine to Pregabalin and placebo to better understand how these treatments impact pain associated with DPN. Participants will be randomly assigned to one of three groups receiving Suzetrigine tablets, Pregabalin capsules, or a placebo that matches either Suzetrigine or Pregabalin. The study is double-blinded and lasts 12 weeks during which participants take the assigned oral medication. The trial actively monitors participants responses to treatment over this period. Participants will be assessed for changes in their daily pain levels using the Numeric Pain Rating Scale NPRS throughout the 12 weeks. Additional evaluations include physical health status measured by the SF-36 questionnaire. Researchers will monitor safety and tolerability during the trial. The total participation duration spans up to 12 weeks from baseline to final assessment.
CONDITIONS
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
M
Medical Information
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Vertex Pharmaceuticals Incorporated
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Suzetrigine | Pregabalin (trial arm) | Pregabalin (standard‑of‑care) |
|---|---|---|---|
| What it is | Oral investigational drug being tested for pain in diabetic peripheral neuropathy | Oral Pregabalin active comparator arm in the trial | Pregabalin is an established first‑line treatment for painful diabetic peripheral neuropathy |
| Role in trial | Investigational treatment being evaluated | Active comparator arm | Represents current guideline‑recommended therapy |
| Primary use | Being evaluated for relief of pain from diabetic peripheral neuropathy | Used to compare pain relief against investigational drug and placebo | Used in routine clinical practice to relieve DPN pain |
| How it is given or performed | Oral tablets | Oral capsules | Oral capsules used in standard practice |
| Evidence status | Effectiveness is being tested; no results available yet | Efficacy established in prior studies and remains standard first‑line option | Supported by clinical guidelines and systematic evidence |
| Important risks | Unknown safety profile until trial results are available | Known adverse effects include dizziness and somnolence reported in prior use | Known to cause dizziness and drowsiness in some patients |
| Important limitations | Efficacy and safety not yet established; trial results pending | Side effects may limit tolerability; some patients may not respond adequately | Commonly used but may not fully relieve pain and may cause adverse effects |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive oral tablets or capsules of Suzetrigine, Pregabalin, or matched placebo as assigned randomly.
Regular visits to monitor progress and safety
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Molly Fensterwald, Jordan Johnson, Angel Moreno...
https://pubmed.ncbi.nlm.nih.gov/42249666/Vertex Pharmaceuticals Incorporated
Lead Sponsor